Hepatocellular adenoma epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (4 intermediate revisions by one other user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{ZAS}} | {{CMG}}; {{AE}} {{ZAS}} | ||
==Overview== | ==Overview== | ||
Hepatocellular adenoma is more common in women in Western countries where they are exposed to higher [[Dose|doses]] of [[Oral contraceptive|oral contraceptives]]. The estimated [[incidence]] is 3 per 100,000 individuals/year and is 3 to 4 per 100,000 individuals with long term history of [[Oral contraceptive|oral contraceptive use]]. It is more common in women of childbearing [[age]] who take [[Oral contraceptive|oral contraceptives]] and can rarely occur in men who take long term [[anabolic]] [[Androgen|androgenic]] [[Steroid|steroids]]. | |||
==Epidemiology and | ==Epidemiology and Demographics== | ||
===Incidence=== | |||
* The estimated [[incidence]] of hepatocellular adenoma is 3 per 100,000 individuals/year.<ref name="pmid18333188">{{cite journal| author=Barthelmes L, Tait IS| title=Liver cell adenoma and liver cell adenomatosis. | journal=HPB (Oxford) | year= 2005 | volume= 7 | issue= 3 | pages= 186-96 | pmid=18333188 | doi=10.1080/13651820510028954 | pmc=PMC2023950 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18333188 }} </ref><ref name="NaultCouchy2017">{{cite journal|last1=Nault|first1=Jean-Charles|last2=Couchy|first2=Gabrielle|last3=Balabaud|first3=Charles|last4=Morcrette|first4=Guillaume|last5=Caruso|first5=Stefano|last6=Blanc|first6=Jean-Frederic|last7=Bacq|first7=Yannick|last8=Calderaro|first8=Julien|last9=Paradis|first9=Valérie|last10=Ramos|first10=Jeanne|last11=Scoazec|first11=Jean-Yves|last12=Gnemmi|first12=Viviane|last13=Sturm|first13=Nathalie|last14=Guettier|first14=Catherine|last15=Fabre|first15=Monique|last16=Savier|first16=Eric|last17=Chiche|first17=Laurence|last18=Labrune|first18=Philippe|last19=Selves|first19=Janick|last20=Wendum|first20=Dominique|last21=Pilati|first21=Camilla|last22=Laurent|first22=Alexis|last23=De Muret|first23=Anne|last24=Le Bail|first24=Brigitte|last25=Rebouissou|first25=Sandra|last26=Imbeaud|first26=Sandrine|last27=Bioulac-Sage|first27=Paulette|last28=Letouzé|first28=Eric|last29=Zucman-Rossi|first29=Jessica|last30=Laurent|first30=Christophe|last31=Saric|first31=Jean|last32=Frulio|first32=Nora|last33=Castain|first33=Claire|last34=Dujardin|first34=Fanny|last35=Benchellal|first35=Zin|last36=Bourlier|first36=Pascal|last37=Azoulay|first37=Daniel|last38=Luciani|first38=Alain|last39=Pageaux|first39=Georges-Philippe|last40=Fabre|first40=Jean-Michel|last41=Vilgrain|first41=Valerie|last42=Belghiti|first42=Jacques|last43=Bancel|first43=Brigitte|last44=Boleslawski|first44=Emmanuel|last45=Letoublon|first45=Christophe|last46=Vaillant|first46=Jean Christophe|last47=Prévôt|first47=Sophie|last48=Castaing|first48=Denis|last49=Jacquemin|first49=Emmanuel|last50=Peron|first50=Jean Marie|last51=Quaglia|first51=Alberto|last52=Paye|first52=François|last53=Terraciano|first53=Luigi|last54=Mazzaferro|first54=Vincenzo|last55=Saint Paul|first55=Marie Christine|last56=Terris|first56=Benoit|title=Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation|journal=Gastroenterology|volume=152|issue=4|year=2017|pages=880–894.e6|issn=00165085|doi=10.1053/j.gastro.2016.11.042}}</ref><ref>{{Cite journal | |||
* The estimated incidence of hepatocellular adenoma is 3 per | | author = [[J. B. Rooks]], [[H. W. Ory]], [[K. G. Ishak]], [[L. T. Strauss]], [[J. R. Greenspan]], [[A. P. Hill]] & [[C. W. Jr Tyler]] | ||
* The annual incidence is substantially higher with long term oral contraceptive use, estimated at 3 to 4 per 100,000, but may be less with newer oral contraceptives. | | title = Epidemiology of hepatocellular adenoma. The role of oral contraceptive use | ||
| journal = [[JAMA]] | |||
| volume = 242 | |||
| issue = 7 | |||
| pages = 644–648 | |||
| year = 1979 | |||
| month = August | |||
| pmid = 221698 | |||
}}</ref> | |||
* The annual [[incidence]] is substantially higher with long term [[Oral contraceptive|oral contraceptive use]], estimated at 3 to 4 per 100,000 individuals, but may be less with newer [[Oral contraceptive|oral contraceptives]]. | |||
== | ===Prevalence=== | ||
==Gender== | * [[Prevalence]] of hepatocellular adenoma is difficult to asses because of the large proportion of adenomas not presenting with conventional [[Symptom|symptoms]]. | ||
* The hepatocellular adenoma is more common in women of childbearing age who take oral contraceptives | * The [[prevalence]] of hepatocellular adenoma was increased in the 1970s following the introduction of [[Oral contraceptive|oral contraception]] in Western countries.<ref name="VédieSutter2018">{{cite journal|last1=Védie|first1=Anne-Laure|last2=Sutter|first2=Olivier|last3=Ziol|first3=Marianne|last4=Nault|first4=Jean-Charles|title=Molecular classification of hepatocellular adenomas: impact on clinical practice|journal=Hepatic Oncology|volume=5|issue=1|year=2018|pages=HEP04|issn=2045-0923|doi=10.2217/hep-2017-0023}}</ref> | ||
===Age=== | |||
* The hepatocellular adenoma is more common in women of childbearing [[age]] who take [[Oral contraceptive|oral contraceptives]].<ref>{{Cite journal | |||
| author = [[L. A. Heinemann]], [[A. Weimann]], [[G. Gerken]], [[C. Thiel]], [[M. Schlaud]] & [[T. DoMinh]] | |||
| title = Modern oral contraceptive use and benign liver tumors: the German Benign Liver Tumor Case-Control Study | |||
| journal = [[The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception]] | |||
| volume = 3 | |||
| issue = 4 | |||
| pages = 194–200 | |||
| year = 1998 | |||
| month = December | |||
| pmid = 10036602 | |||
}}</ref><ref name="NaultParadis2017">{{cite journal|last1=Nault|first1=Jean-Charles|last2=Paradis|first2=Valérie|last3=Cherqui|first3=Daniel|last4=Vilgrain|first4=Valérie|last5=Zucman-Rossi|first5=Jessica|title=Molecular classification of hepatocellular adenoma in clinical practice|journal=Journal of Hepatology|volume=67|issue=5|year=2017|pages=1074–1083|issn=01688278|doi=10.1016/j.jhep.2017.07.009}}</ref> | |||
===Gender=== | |||
* The hepatocellular adenoma is more common in women of childbearing [[age]] who take [[Oral contraceptive|oral contraceptives]].<ref name="NaultParadis2017" /> | |||
*It can also rarely develop in men with long term [[anabolic]] [[androgenic]] [[steroids]] use.<ref>{{Cite journal | |||
| author = [[G. B. Coombes]], [[J. Reiser]], [[F. J. Paradinas]] & [[I. Burn]] | |||
| title = An androgen-associated hepatic adenoma in a trans-sexual | |||
| journal = [[The British journal of surgery]] | |||
| volume = 65 | |||
| issue = 12 | |||
| pages = 869–870 | |||
| year = 1978 | |||
| month = December | |||
| pmid = 737424 | |||
}}</ref> | |||
==References== | ==References== | ||
Latest revision as of 16:34, 20 August 2019
|
Hepatocellular adenoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hepatocellular adenoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Hepatocellular adenoma epidemiology and demographics |
|
Hepatocellular adenoma epidemiology and demographics in the news |
|
Blogs on Hepatocellular adenoma epidemiology and demographics |
|
Risk calculators and risk factors for Hepatocellular adenoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD[2]
Overview
Hepatocellular adenoma is more common in women in Western countries where they are exposed to higher doses of oral contraceptives. The estimated incidence is 3 per 100,000 individuals/year and is 3 to 4 per 100,000 individuals with long term history of oral contraceptive use. It is more common in women of childbearing age who take oral contraceptives and can rarely occur in men who take long term anabolic androgenic steroids.
Epidemiology and Demographics
Incidence
- The estimated incidence of hepatocellular adenoma is 3 per 100,000 individuals/year.[1][2][3]
- The annual incidence is substantially higher with long term oral contraceptive use, estimated at 3 to 4 per 100,000 individuals, but may be less with newer oral contraceptives.
Prevalence
- Prevalence of hepatocellular adenoma is difficult to asses because of the large proportion of adenomas not presenting with conventional symptoms.
- The prevalence of hepatocellular adenoma was increased in the 1970s following the introduction of oral contraception in Western countries.[4]
Age
- The hepatocellular adenoma is more common in women of childbearing age who take oral contraceptives.[5][6]
Gender
- The hepatocellular adenoma is more common in women of childbearing age who take oral contraceptives.[6]
- It can also rarely develop in men with long term anabolic androgenic steroids use.[7]
References
- ↑ Barthelmes L, Tait IS (2005). "Liver cell adenoma and liver cell adenomatosis". HPB (Oxford). 7 (3): 186–96. doi:10.1080/13651820510028954. PMC 2023950. PMID 18333188.
- ↑ Nault, Jean-Charles; Couchy, Gabrielle; Balabaud, Charles; Morcrette, Guillaume; Caruso, Stefano; Blanc, Jean-Frederic; Bacq, Yannick; Calderaro, Julien; Paradis, Valérie; Ramos, Jeanne; Scoazec, Jean-Yves; Gnemmi, Viviane; Sturm, Nathalie; Guettier, Catherine; Fabre, Monique; Savier, Eric; Chiche, Laurence; Labrune, Philippe; Selves, Janick; Wendum, Dominique; Pilati, Camilla; Laurent, Alexis; De Muret, Anne; Le Bail, Brigitte; Rebouissou, Sandra; Imbeaud, Sandrine; Bioulac-Sage, Paulette; Letouzé, Eric; Zucman-Rossi, Jessica; Laurent, Christophe; Saric, Jean; Frulio, Nora; Castain, Claire; Dujardin, Fanny; Benchellal, Zin; Bourlier, Pascal; Azoulay, Daniel; Luciani, Alain; Pageaux, Georges-Philippe; Fabre, Jean-Michel; Vilgrain, Valerie; Belghiti, Jacques; Bancel, Brigitte; Boleslawski, Emmanuel; Letoublon, Christophe; Vaillant, Jean Christophe; Prévôt, Sophie; Castaing, Denis; Jacquemin, Emmanuel; Peron, Jean Marie; Quaglia, Alberto; Paye, François; Terraciano, Luigi; Mazzaferro, Vincenzo; Saint Paul, Marie Christine; Terris, Benoit (2017). "Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation". Gastroenterology. 152 (4): 880–894.e6. doi:10.1053/j.gastro.2016.11.042. ISSN 0016-5085.
- ↑ J. B. Rooks, H. W. Ory, K. G. Ishak, L. T. Strauss, J. R. Greenspan, A. P. Hill & C. W. Jr Tyler (1979). "Epidemiology of hepatocellular adenoma. The role of oral contraceptive use". JAMA. 242 (7): 644–648. PMID 221698. Unknown parameter
|month=ignored (help) - ↑ Védie, Anne-Laure; Sutter, Olivier; Ziol, Marianne; Nault, Jean-Charles (2018). "Molecular classification of hepatocellular adenomas: impact on clinical practice". Hepatic Oncology. 5 (1): HEP04. doi:10.2217/hep-2017-0023. ISSN 2045-0923.
- ↑ L. A. Heinemann, A. Weimann, G. Gerken, C. Thiel, M. Schlaud & T. DoMinh (1998). "Modern oral contraceptive use and benign liver tumors: the German Benign Liver Tumor Case-Control Study". The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception. 3 (4): 194–200. PMID 10036602. Unknown parameter
|month=ignored (help) - ↑ 6.0 6.1 Nault, Jean-Charles; Paradis, Valérie; Cherqui, Daniel; Vilgrain, Valérie; Zucman-Rossi, Jessica (2017). "Molecular classification of hepatocellular adenoma in clinical practice". Journal of Hepatology. 67 (5): 1074–1083. doi:10.1016/j.jhep.2017.07.009. ISSN 0168-8278.
- ↑ G. B. Coombes, J. Reiser, F. J. Paradinas & I. Burn (1978). "An androgen-associated hepatic adenoma in a trans-sexual". The British journal of surgery. 65 (12): 869–870. PMID 737424. Unknown parameter
|month=ignored (help)